CEA

Commissariat à l'Energie Atomique et aux Energies Alternatives, Orsay, France

Group Description

Brief description of legal entity
The Institute for Biomedical Imaging (I2BM) is one of eight institutes in the Life Sciences Division (DSV) of the fundamental research pole of the Atomic Energy Commission (CEA). Consistent with its affiliation to the CEA, the Institute functions are at the interface of technological and fundamental research. Its missions are to develop, maintain and make available to the entire scientific, academic and industrial community, imaging methods and technologies allowing the refinement and monitoring of innovative therapeutic and diagnostic strategies, and in particular in the field of neurodegenerative diseases. CEA/I2BM is based on strong interdisciplinary links between basic researchers and medical imaging scientists involving in faculties of medicine, chemistry and pharmacy, mathematics and computer sciences and physics and as such collects a broad spectrum of expertise from isotopic radiochemistry to medicine.
As a part of the CEA (French Atomic Energy and Alternative Energies Commission), the National Institute for Nuclear Science and Technology (INSTN) is a higher education institution under the joint supervision of the Ministry of Higher Education and Research, the Ministry of Ecology, Sustainable Development and Energy, and the Ministry of Industry. The INSTN’s mission is to disseminate knowledge and know-how developed at the CEA.

Main tasks
CEA/I2BM focuses its scientific work on the development of new radioligands for PET imaging of neuroinflammation. The most important applications comprise radiosynthesis of novel chemical structures labelled with the short-lived positron-emitters carbon-11 and fluorine-18 as well as imaging studies in animal models (rodent and non-human-primates), which can be translated into clinical applications.

Participation in INMiND: WP3 / WP4 / WP5 / WP7 / WP8 / WP10 / WP12 (leader).

Previous experience relevant to INMiND tasks

Multi-modal imaging of experimental models by μPET, PET, PET/CT and optical imaging, and of patients by PET/CT; carbon-11/fluorine-18 radiotracer design and development; data quantification and metabolism determination; Coordination of FP6 NoE EMIL (www.emil.eu). Member of the FP6 NoE DiMI (www.dimi.eu). Founding member of the European Society for Molecular Imaging (ESMI). Scientific director of the European Master on Molecular Imaging (EMMI, www.e-mmi.eu). CEA/I2BM has established a broad research programme in neuroinflammation and has notably 1) radiolabelled with carbon-11 and fluorine-18 a dozen of novel TSPO radioligands including 11C-SSR180575 and 18F-DPA-714 and 2) evaluated all these novel compounds using µTEP on specific rodent model of neurodegenerative diseases.


Atomic Energy Commission
Frédéric DOLLÉ, PhD
INMiND Office
European Institute for Molecular Imaging (EIMI) Waldeyerstr. 15
· 48149 Münster
Tel: +49 251 83 49300 · Fax: +49 251 83 49313
E-Mail: